Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2003 Sep;80(Suppl 3):iii59–iii66. doi: 10.1093/jurban/jtg083

HIV prevention among injection drug users: The need for integrated models

David S Metzger 1,✉, Helen Navaline 1
PMCID: PMC3456261  PMID: 14713672

Abstract

Opportunistic infections (OIs) were first recognized among injection drug users (IDUs) in New York City in 1981. By the mid-1980s, OIs had become associated with HIV infection, and attention began to focus on efforts to prevent HIV transmission among IDUs. Since then, a range of prevention strategies has been implemented and evaluated in an attempt to reduce the spread of HIV infection among drug users. These prevention strategies include (1) HIV testing and counseling and educational and behavioural interventions delivered through community outreach; (2) condom, bleach, and needle distribution and syringe access and exchange programs: (3) substance abuse treatment; and, more recently, (4) prevention interventions targeting HIV-positive IDUs. Data from evaluations of these strategies over the past 20 years have provided substantial evidence of effectiveness and have helped to inform network-based and structural interventions. Despite the cumulative empirical evidence, however, research findings have yet to be widely, disseminated, adopted, and implemented in a sustained and integrated fashion. The reasons for this are unclear, but point to a need for improved communications with program developers and community planners to facilitate the implementation and evaluation of integrated intervention strategies, and for collaborative research to help understand policy, legal, economic, and local barriers to implementation.

Keywords: HIV infection, Injection drug users, AIDS, Prevention

Full Text

The Full Text of this article is available as a PDF (65.7 KB).

References

  • 1.Centers for Disease Control Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR Morb Mortal Wkly Rep. 1984;33:377–379. [PubMed] [Google Scholar]
  • 2.Needle RH, Coyle SL, Normand J, Lambert E, Cesari H. HIV prevention with drug-using populations-current status and future prospects: introduction and overview. Public Health Rep. 1998;113(suppl 1):4–18. [PMC free article] [PubMed] [Google Scholar]
  • 3.The NIDA Community-Based Outreach Model. Washington, DC: National Institutes of Health, NIDA; 2000. [Google Scholar]
  • 4.Coyle SL, Needle RH, Normand J. Outreach-based HIV prevention for injecting drug users: a review of published outcome data. Public Health Rep. 1998;113(suppl 1):19–30. [PMC free article] [PubMed] [Google Scholar]
  • 5.Neaigus A. The network approach and interventions to prevent HIV among injection drug users. Public Health Rep. 1998;113(suppl 1):140–150. [PMC free article] [PubMed] [Google Scholar]
  • 6.Latkin CA, Mandell W, Vlahov D, Oziemkowska M, Celentano DD. The long-term outcome of a personal network-oriented HIV prevention intervention for injection drug users: the SAFE study. Am J Community Psychol. 1996;24(3):341–364. doi: 10.1007/BF02512026. [DOI] [PubMed] [Google Scholar]
  • 7.Latkin CA. Outreach in natural settings: the use of peer leaders for HIV prevention among injecting drug users’ networks. Public Health Rep. 1998;113(suppl 1):151–159. [PMC free article] [PubMed] [Google Scholar]
  • 8.Lurie P, Reingold A. The Public Health Impact of Needle Exchange Programs in the United States and Abroad. Berkeley, CA: University of California, School of Public Health; 1993. [Google Scholar]
  • 9.Normand J, Vlahov D, Moses LE, editors. Preventing HIV Transmission: The Role of Sterile Needles and Bleach. Washington, DC: National Academy of Medicine; 1995. [PubMed] [Google Scholar]
  • 10.Needle Exchange Programs: Promise as an AIDS Prevention Strategy. Washington, DC: Government Printing Office; 1993. [Google Scholar]
  • 11.Doherty M, Junge B, Rathouz P, Riley E, Vlahov D. The effects of needle exchange programs on numbers of discarded needles. Am J Public Health. 2000;90(6):936–939. doi: 10.2105/ajph.90.6.936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hagan H, McGough JP, Thiede H, Hopkins S, Duchin J, Alexander ER. Reduced injection frequency and increased entry and retention in substance abuse treatment associated with needle-exchange participation in Seattle drug injectors. J Subst Abuse Treat. 2000;19(3):247–252. doi: 10.1016/S0740-5472(00)00104-5. [DOI] [PubMed] [Google Scholar]
  • 13.Coffin P. Syringe availability as HIV prevention: a review of modalities. J Urban Health. 2000;77(3):306–330. doi: 10.1007/BF02386743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Vlahov D, Jarlais DC, Goosby E, et al. Needle exchange programs for the prevention of HIV infection: epidemiology and policy. Am J Epidemiol. 2001;154(12 suppl):S70–S77. doi: 10.1093/aje/154.12.S70. [DOI] [PubMed] [Google Scholar]
  • 15.Monterroso ER, Hamburger ME, Vlahov D, et al. Prevention of infection in street recruited injection drug users: the Collaborative Injection Drug Users Study. J Acquir Immune Defic Syndr. 2000;25:63–70. doi: 10.1097/00042560-200009010-00009. [DOI] [PubMed] [Google Scholar]
  • 16.Rich JD, Macalino GE, McKenzie M, Taylor LE, Burris S. Syringe prescription to prevent HIV infection in Rhode Island: a case study. Am J Public Health. 2001;91(5):699–700. doi: 10.2105/ajph.91.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Burris S, Lurie P, Abrahamson D, Rich JD. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Ann Intern Med. 2000;133(3):218–226. doi: 10.7326/0003-4819-133-3-200008010-00015. [DOI] [PubMed] [Google Scholar]
  • 18.Fuller CM, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc. 2002;42(6 suppl 2):S77–S82. doi: 10.1331/1086-5802.42.0.s77.fuller. [DOI] [PubMed] [Google Scholar]
  • 19.Reich W, Compton W, Horton JC, et al. Injection drug users report good access to pharmacy sales of syringes. J Am Pharm Assoc. 2002;42(6 suppl 2):S68–S71. doi: 10.1331/1086-5802.42.0.s68.reich. [DOI] [PubMed] [Google Scholar]
  • 20.Ball JC, Lange RL, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav. 1988;29:214–226. doi: 10.2307/2137033. [DOI] [PubMed] [Google Scholar]
  • 21.Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer Verlag; 1991. [Google Scholar]
  • 22.Booth RE, Crowley T, Zhang Y. Substance abuse treatment entry, retention and effectiveness: out-of-treatment opiate injection drug users. Drug Alcohol Depend. 1996;42(1):11–20. doi: 10.1016/0376-8716(96)01257-4. [DOI] [PubMed] [Google Scholar]
  • 23.Etheridge RM, Craddock SG, Hubbard RI, Rounds-Bryant JL. The relationship of counseling and self-help participation to patient outcomes in DATOS. Drug Alcohol Depend. 1999;57(2):99–112. doi: 10.1016/S0376-8716(99)00087-3. [DOI] [PubMed] [Google Scholar]
  • 24.Caplehorn JRM, Ross MW. Methadone maintenance and the likelihood of risky needle sharing. Int J Addict. 1995;30:685–698. doi: 10.3109/10826089509048753. [DOI] [PubMed] [Google Scholar]
  • 25.Jarlais DC, Abdul-Quarder AS, Tross S. The next problem: maintenance of AIDS risk reduction among intravenous drug users. Int J Addict. 1991;26(12):1279–1292. doi: 10.3109/10826089109062160. [DOI] [PubMed] [Google Scholar]
  • 26.Avants SK, Margolin A, Sindelar JL, et al. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. Am J Psychiatry. 1999;156(1):27–33. doi: 10.1176/ajp.156.1.27. [DOI] [PubMed] [Google Scholar]
  • 27.Gossop M, Marsden J, Stewert D, Treacy S. Reduced injection risk and sexual risk behaviours after drug misuse treatment: results from the National Treatment Outcome Research Study. AIDS Care. 2002;14(1):77–93. doi: 10.1080/09540120220097955. [DOI] [PubMed] [Google Scholar]
  • 28.Avins AL, Lindan CP, Woods WJ, et al. Changes in HIV-related behaviours among heterosexual alcoholics following addiction treatment. Drug Alcohol Depend. 1997;44(1):47–55. doi: 10.1016/S0376-8716(96)01321-X. [DOI] [PubMed] [Google Scholar]
  • 29.Novick DM, Kreek MJ, Jarlais DC, et al. NIDA Research Monograph 67: Problems of Drug Dependence. Washington, DC: National Institute on Drug Abuse; 1985. Abstract of clinical research findings: therapeutic and historical aspects; pp. 318–320. [Google Scholar]
  • 30.Brown LS, Burkette W, Primm BJ. Drug treatment and HIV seropositivity. NY State J Med. 1988;88(3):156–156. [PubMed] [Google Scholar]
  • 31.Novick DM, Joseph H, Croxon TS, et al. Absence of antibody to human immunodeficieney virus in long term, socially rehabilitated methadone maintenance patients. Arch Intern Med. 1990;150:97–99. doi: 10.1001/archinte.150.1.97. [DOI] [PubMed] [Google Scholar]
  • 32.Blix O, Gronbladh L. Impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: Loimer N, Schmid R, Springer A, editors. Drug Addiction and AIDS. New York, NY: Springer-Verlag; 1991. pp. 200–205. [Google Scholar]
  • 33.Moss AR, Vranizan K, Gorter R, Bachetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS. 1994;8(2):223–231. doi: 10.1097/00002030-199402000-00010. [DOI] [PubMed] [Google Scholar]
  • 34.Williams AB, McNelly EA, Williams AE, D’Aquila RT. Methadone maintenance treatment and HIV type 1 seroconversion among injection drug users. AIDS Care. 1992;4:35–41. doi: 10.1080/09540129208251618. [DOI] [PubMed] [Google Scholar]
  • 35.Serpelloni G, Carriere MP, Rezza G, Morganti S, Gomma M, Binkin N. Methadone treatment as a determinant of HIV risk reduction among injecting drug users: a nested case-controlled study. AIDS Care. 1994;6:215–220. doi: 10.1080/09540129408258632. [DOI] [PubMed] [Google Scholar]
  • 36.Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among in- and out-of-treatment intravenous drug users: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049–1056. [PubMed] [Google Scholar]
  • 37.Friedman SR, Jose B, Deren S, Jarlais DC, Neaigus A. Risk factors for HIV seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. Am J Epidemiol. 1995;142:864–874. doi: 10.1093/oxfordjournals.aje.a117726. [DOI] [PubMed] [Google Scholar]
  • 38.Thiede H, Hagan H, Murrill CS. Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. J Urban Health. 2000;77:331–344. doi: 10.1007/BF02386744. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Metzger D, Navaline H, Woody G. Substance abuse treatment as HIV prevention. Public Health Rep. 1998;118(suppl 1):97–106. [PMC free article] [PubMed] [Google Scholar]
  • 40.Sorensen J, Copeland A. Substance abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000;59:17–31. doi: 10.1016/S0376-8716(99)00104-0. [DOI] [PubMed] [Google Scholar]
  • 41.Haverkos HW. HIv/AIDS and drug abuse: epidemiology and prevention. J Addict Dis. 1998;4:91–103. doi: 10.1300/J069v17n04_08. [DOI] [PubMed] [Google Scholar]
  • 42.Etheridge RM, craddock SG, Dunteman GH, Hubbard RL. Treatment services in two national studies of community-based substance abuse treatment programs. J Subst Abuse. 1995;7:9–26. doi: 10.1016/0899-3289(95)90303-8. [DOI] [PubMed] [Google Scholar]
  • 43.Shuster CR. Intravenous drug use and HIV prevention. Public Health Rep. 1988;103:261–263. [PMC free article] [PubMed] [Google Scholar]
  • 44.Knowlton AR, Hoover DR, Chung SE, Celentano DD, Vlahov D, Latkin CA. Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug Alcohol Depend. 2001;64(1):55–62. doi: 10.1016/S0376-8716(00)00228-3. [DOI] [PubMed] [Google Scholar]
  • 45.Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285(18):2355–2362. doi: 10.1001/jama.285.18.2355. [DOI] [PubMed] [Google Scholar]
  • 46.Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707–1715. doi: 10.1097/00002030-200109070-00015. [DOI] [PubMed] [Google Scholar]
  • 47.Laine C, Hauck WW, Turner BJ. Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Med Care. 2002;40(10):976–995. doi: 10.1097/00005650-200210000-00014. [DOI] [PubMed] [Google Scholar]
  • 48.Laine C, Zhang D, Hauck WW, Turner BJ. HIV-1 RNA viral load monitoring in HIV-infected drug users on antiretroviral therapy: relationship with outpatient care patierns. J Acquir Immune Defic Syndr. 2002;29(3):270–274. doi: 10.1097/00126334-200203010-00007. [DOI] [PubMed] [Google Scholar]
  • 49.Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–381. doi: 10.1046/j.1525-1497.2002.10644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES